Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats

Journal of Pharmacological Sciences

Volumn 111, Issue 2, 2009, Pages 193-200

  Okada, Muneyoshi ^a   Harada, Toshiyuki ^a   Kikuzuki, Ryuta ^a   Yamawaki, Hideyuki ^a   Hara, Yukio ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Angiotensin II type 1 receptor; Matrix metalloproteinase; Monocrotaline; Right ventricular remodeling; Telmisartan

Indexed keywords

GELATINASE A; GELATINASE B; MONOCROTALINE; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; FLOW RATE; HEART INDEX; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE CONTRACTION; HEART VENTRICLE EJECTION TIME; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT;

EID: 70350509631     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09112FP     Document Type: Article

References (33)

1. van Wolferen SA, Grünberg K, Vonk Noordegraaf A. Diagnosis and management of pulmonary hypertension over the past 100 years. Respir Med. 2007;101:389-398. (Pubitemid 46196343)
2. Campian ME, Hardziyenka M, Michel MC, Tan HL. How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol. 2006;373: 391-400.
3. Ghodsi F, Will JA. Changes in pulmonary structure and function induced by monocrotaline intoxication. Am J Physiol. 1981; 240:H149-H155. (Pubitemid 11155908)
4. Chen L, Gan XT, Haist JV, Feng Q, Lu X, Chakrabarti S, et al. Attenuation of compensatory right ventricular hypertrophy and heart failure following monocrotaline-induced pulmonary vascular injury by the Na+-H+ exchange inhibitor cariporide. J Pharmacol Exp Ther. 2001;298:469-476. (Pubitemid 32673396)
5. Hessel HM, Steendijk P, den Adel B, Schutte CI, van der Laarse A. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol. 2006;291:H2424-H2430. (Pubitemid 44776673)
6. Lamberts RR, Caldenhoven E, Lansink M, Witte G, Vaessen RJ, St Cyr JA, et al. Preservation of diastolic function in monocrotaline-induced right ventricular hypertrophy in rats. Am J Physiol Heart Circ Physiol. 2007;293:H1869-H1876. (Pubitemid 47367237)
7. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827-839. (Pubitemid 36542523)
8. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007;117:568-575. (Pubitemid 46348511)
9. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007;87:1285-1342. (Pubitemid 350041472)
10. Umar S, Hessel M, Steendijk P, Bax W, Schutte C, Schalij M, et al. Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension. Pathol Res Pract. 2007;203:863-872. (Pubitemid 350048629)
11. Park HK, Park SJ, Kim CS, Paek YW, Lee JU, Lee WJ. Enhanced gene expression of renin-angiotensin system, TGF-beta1, endothelin-1 and nitric oxide synthase in right-ventricular hypertrophy. Pharmacol Res. 2001;43:265-273.
12. Lourenço AP, Roncon-Albuquerque R Jr, Brás-Silva C, Faria B, Wieland J, Henriques-Coelho T, et al. Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats. Am J Physiol Heart Circ Physiol. 2006;291:H1587-H1594. (Pubitemid 44497662)
13. Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H, Hara Y. Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci. 2008;108:487-494.
14. Cassis LA, Rippetoe PE, Soltis EE, Painter DJ, Fitz R, Gillespie MN. Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist. J Pharmacol Exp Ther. 1992;262:1168-1172.
15. Kishi K, Jin D, Takai S, Muramatsu M, Katayama H, Tamai H, et al. Role of chymase-dependent angiotensin II formation in monocrotaline-induced pulmonary hypertensive rats. Pediatr Res. 2006;60:77-82. (Pubitemid 44297617)
16. Grassi G, Quarti-Trevano F, Mancia G. Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension. J Renin Angiotensin Aldosterone Syst. 2008;9:66-74. (Pubitemid 352005738)
17. Jones JE, Mendes L, Rudd MA, Russo G, Loscalzo J, Zhang YY. Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am J Physiol Heart Circ Physiol. 2002;283:H364-H371. (Pubitemid 34705359)
18. Kato Y, Iwase M, Kanazawa H, Kawata N, Yoshimori Y, Hashimoto K, et al. Progressive development of pulmonary hypertension leading to right ventricular hypertrophy assessed by echocardiography in rats. Exp Anim. 2003;52:285-294. (Pubitemid 41349959)
19. Hardziyenka M, Campian ME, de Bruin-Bon HA, Michel MC, Tan HL. Sequence of echocardiographic changes during development of right ventricular failure in rat. J Am Soc Echocardiogr. 2006;19:1272-1279. (Pubitemid 44416169)
20. Handoko ML, Schalij I, Kramer K, Sebkhi A, Postmus PE, van der Laarse WJ, et al. A refined radio-telemetry technique to monitor right ventricle or pulmonary artery pressures in rats: a useful tool in pulmonary hypertension research. Pflugers Arch. 2008;455:951-959. (Pubitemid 350265617)
21. Nakamoto T, Harasawa H, Akimoto K, Hirata H, Kaneko H, Kaneko N, et al. Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats. Eur J Pharmacol. 2005;528:43-51. (Pubitemid 41773650)
22. Deschamps AM, Spinale FG. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res. 2006;69:666-676.
23. Takenaka H, Kihara Y, Iwanaga Y, Onozawa Y, Toyokuni S, Kita T. Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension. J Mol Cell Cardiol. 2006;41:989-997. (Pubitemid 44791331)
24. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423-432. (Pubitemid 38970186)
25. Unger T. Significance of angiotensin type 1 blockade: why are angiotensin II receptor blockers different? Am J Cardiol. 1999;84:9S-15S.
26. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904-912.
27. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol. 2004;6:499-506. (Pubitemid 38786592)
28. Saygili E, Rana OR, Saygili E, Reuter H, Frank K, Schwinger RH, et al. Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes. Am J Physiol Heart Circ Physiol. 2007;292:H2898-H2905. (Pubitemid 47084539)
29. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109:2054-2057. (Pubitemid 38620211)
30. Benson SC, Pershadsinqh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43:993-1002. (Pubitemid 38579904)
31. Duan SZ, Ivashchenko CY, Usher MG, Mortensen RM. PPARgamma in the cardiovascular system. PPAR Res. 2008;2008:1-10.
32. Nakamura T, Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong YF, et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension. 2008;51:296-301. (Pubitemid 351159942)
33. Kobayashi N, Ohno T, Yoshida K, Fukushima H, Mamada Y, Nomura M, et al. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens. 2008;21:576-581. (Pubitemid 351589680)